Last Update Time: 13-Mar-2025 11:47:47
ISIN: INE878I01022
Sector: Healthcare
Symbol: BAFNAPH

Bafna Pharmaceuticals Limited

₹82.00 ₹0.74 (0.91%) ▲
Prev. Close ₹81.26
Open ₹81.26
Close ₹0.00
Range ₹77.90 - ₹86.10
High ₹82.00
Low ₹81.00
Ind. Close ₹0.00
VWAP ₹81.29

The current stock price of Bafna Pharmaceuticals Limited is ₹82.00, with a target price range between ₹77.90 and ₹86.10. The stock has experienced a price change of ₹0.74 (0.91%), reflecting recent market volatility.

Today's opening price was ₹81.26, while the previous close stood at ₹81.26.

The market trend suggests an uptrend, making it an attractive investment opportunity for traders seeking short-term gains.

For real-time stock market updates, live share prices, and stock analysis, stay tuned. Understanding key stock metrics like VWAP, high-low range, and market momentum can help traders make informed investment decisions.

Bafna Pharmaceuticals Limited Price Chart

Bafna Pharmaceuticals Limited Pre Open Market Overview: 13-Mar-2025

Key Metrics:

  • IEP (Indicative Equilibrium Price): 0
  • Previous Close Price: 81.26
  • Change: -81.26%
  • Total Traded Volume: 0
  • Total Buy Quantity: 200
  • Total Sell Quantity: 713
Price Buy Qty Sell Qty
0.00 0.00 0.00
77.19 100.00 0.00
78.00 100.00 0.00
82.50 0.00 258.00
82.60 0.00 50.00
83.90 0.00 100.00
85.00 0.00 205.00

ATO Data:

  • Buy Quantity (ATO): 0
  • Sell Quantity (ATO): 205

Order Book

Bid Qty Ask Qty
82.00 6 82.48 100
80.50 250 82.49 50
78.53 50 82.50 258
78.52 500 83.90 200
78.50 50 84.80 30
Total Buy Quantity: 200 Total Sell Quantity: 713

Shareholding Patterns of Bafna Pharmaceuticals Limited

Key Trade Statistics of Bafna Pharmaceuticals Limited

Trade Information Details
Traded Volume (Lakhs) 0.01
Traded Value (₹ Cr.) 0.01
Total Market Cap (₹ Cr.) 193.98
Free Float Market Cap (₹ Cr.) 22.69
Impact cost 2.29
Quantity Traded N/A
Deliverable Quantity N/A
% of Quantity to Traded N/A
Security VaR N/A
Index VaR N/A
VaR Margin 100
Extreme Loss Rate N/A
Adhoc Margin N/A
Applicable Margin Rate 100
Face Value 10

Key Price Statistics of Bafna Pharmaceuticals Limited

The 52-week high for Bafna Pharmaceuticals Limited was ₹113.00, recorded on 07-May-2024. On the other hand, the 52-week low stands at ₹69.00, with the lowest value recorded on 19-Feb-2025.

The upper band for trading is ₹85.32, and the lower band is ₹77.19. The price band is 5%.

The stock's daily volatility stands at 2.80, while the annualized volatility is 53.49. The tick size for trading is ₹0.01.

Price Information Details
52 Week High (07-May-2024) 113.00
52 Week Low (19-Feb-2025) 69.00
Upper Band 85.32
Lower Band 77.19
Price Band (%) 5
Daily Volatility 2.80
Annualised Volatility 53.49
Tick Size 0.01

Key Securities Statistics of Bafna Pharmaceuticals Limited

Securities Information Details
Status Listed
Trading Status Active
Date of Listing 27-Feb-2020
Adjusted P/E 41.31
Symbol P/E 44.74
Index NA
Macro-Economic Sector Healthcare
Sector Healthcare
Industry Pharmaceuticals & Biotechnology
Basic Industry Pharmaceuticals

Security Status of Bafna Pharmaceuticals Limited

Title Details
Board Status Main
Trading Segment Normal Market
Session No. -
Class of Shares Equity
SDD Compliance -
Name of Compliance Officer -

Announcements of Bafna Pharmaceuticals Limited

Subject Date
Copy of Newspaper Publication 11-Feb-2025
Integrated Filing- Financial 06-Feb-2025
Outcome of Board Meeting 06-Feb-2025
Financial Result Updates 06-Feb-2025
Board Meeting Intimation 28-Jan-2025
Certificate under SEBI (Depositories and Participants) Regulations, 2018 09-Jan-2025
Trading Window-XBRL 25-Dec-2024
Trading Window 25-Dec-2024

Corporate Actions of Bafna Pharmaceuticals Limited

Face Value Purpose Ex-Date Start Date End Date
10 Annual General Meeting 17-Sep-2024 19-Sep-2024 25-Sep-2024
10 Annual General Meeting 20-Jul-2022 22-Jul-2022 28-Jul-2022
10 Annual General Meeting 05-Aug-2021 07-Aug-2021 14-Aug-2021
10 Annual General Meeting 23-Jul-2020 25-Jul-2020 31-Jul-2020

Board Meetings of Bafna Pharmaceuticals Limited

Purpose Details Att. Mtg. Date
Board Meeting Intimation BAFNA PHARMACEUTICALS LIMITED has informed the Exchange about Board Meeting to be held on 06-Feb-2025 to inter-alia consider and approve the Unaudited Financial results of the Company for the Quarterly ended December 2024 . 06-Feb-2025
Financial Results To consider and approve the unaudited financial results for the period ended December 31, 2024 06-Feb-2025
Board Meeting Intimation BAFNA PHARMACEUTICALS LIMITED has informed the Exchange about Board Meeting to be held on 11-Nov-2024 to inter-alia consider and approve the Unaudited Financial results of the Company for the Quarterly ended September 2024 . 11-Nov-2024
Financial Results To consider and approve the Unaudited Financial Results for the period ended September 30, 2024 11-Nov-2024
BAFNA PHARMACEUTICALS LIMITED has informed the Exchange about Board Meeting to be held on 13-Aug-2024 to inter-alia consider and approve the Unaudited Financial results of the Company for the Quarterly ended June 2024 . Board Meeting Intimation 13-Aug-2024
Financial Results To consider and approve the Unaudited financial results for the period ended Jun 30, 2024 13-Aug-2024
BAFNA PHARMACEUTICALS LIMITED has informed the Exchange about Board Meeting to be held on 29-May-2024 to inter-alia consider and approve the Audited Financial results of the Company for the Yearly ended March 2024 . Board Meeting Intimation 29-May-2024
Financial Results To consider and approve the Audited Financial Results of the Company for the quarter and year ended March 31, 2024 29-May-2024
Financial Results To consider and approve the un-audited financial results for the period ended December 31, 2023 12-Feb-2024
BAFNA PHARMACEUTICALS LIMITED has informed the Exchange about Board Meeting to be held on 12-Feb-2024 to inter-alia consider and approve the Unaudited Financial results of the Company for the Quarterly ended December 2023 . Board Meeting Intimation 12-Feb-2024
BAFNA PHARMACEUTICALS LIMITED has informed the Exchange about Board Meeting to be held on 09-Nov-2023 to inter-alia consider and approve the Unaudited Financial results of the Company for the Half Yearly ended September 2023 . Board Meeting Intimation 09-Nov-2023
Financial Results To consider and approve the financial results for the period ended September 30, 2023 09-Nov-2023
BAFNA PHARMACEUTICALS LIMITED has informed the Exchange about Board Meeting to be held on 11-Aug-2023 to inter-alia consider and approve the Unaudited Financial results of the Company for the Quarterly ended June 2023 . Board Meeting Intimation 11-Aug-2023
Financial Results To consider and approve the financial results for the period ended Jun 30, 2023 11-Aug-2023
BAFNA PHARMACEUTICALS LIMITED has informed the Exchange about Board Meeting to be held on 26-Jun-2023 to consider Other business. Board Meeting Intimation 26-Jun-2023
Other business matters To consider and approve the appointment of 1. Mr. Vinayak Dinesh Dendukuri (DIN: 07601309) as Additional Director designated as Whole-time Director Operation.2. Mr. Upendar Mekala Reddy (DIN: 08898174) as Additional Director designated as Non-Executive Non-independent Director;3. Mr. Krishna Yeachuri (DIN: 00066898) as Additional Director designated as Non-Executive Independent Director, and any other business with the permission of the Chair. 26-Jun-2023
Financial Results BAFNAPH : 27-May-2023 : The Company has informed the Exchange that a Board meeting to be held on May 24, 2023 has been re-scheduled. Further, the Company has informed the Exchange that the meeting of the Board of Directors of the Company will be held on May 27, 2023, To consider and approve the financial results for the period ended March 31, 2023 24-May-2023
BAFNA PHARMACEUTICALS LIMITED has informed the Exchange about Board Meeting to be held on 27-May-2023 to inter-alia consider and approve the Audited Financial results of the Company for the Yearly ended March 2023 . Board Meeting Intimation 27-May-2023
BAFNA PHARMACEUTICALS LIMITED has informed the Exchange about Board Meeting to be held on 24-May-2023 to inter-alia consider and approve the Audited Financial results of the Company for the Yearly ended March 2023 . Board Meeting Intimation 24-May-2023
Financial Results To consider and approve the financial results for the period ended March 31, 2023 24-May-2023

Financial Results of Bafna Pharmaceuticals Limited

Company Directory of Bafna Pharmaceuticals Limited

Web Address SM Name Office Address City Pincode Telephone Email
N/A Bafna Pharmaceuticals Limited Registered Office No.299
Thambu Chetty Street, Chennai
CHENNAI 600001 044-42677555, 25267517 cs@bafnapharma.com

Insider Trading of Bafna Pharmaceuticals Limited

Reg. Clause Acq./Disp. Sec. (No.) Sec. Value Txn Type Bcast Time
7(2) SRJR LIFESCIENCES LLP 8897 916568 Sell 22-Sep-2022 10:41
7(2) SRJR LIFESCIENCES LLP 9883 1083892 Sell 17-Sep-2022 16:59
7(2) SRJR LIFESCIENCES LLP 27218 3348636 Sell 17-Jun-2022 17:30
7(2) SRJR LIFESCIENCES LLP 13135 1668145 Sell 09-Jun-2022 11:11
7(2) SRJR LIFESCIENCES LLP 11123 1368129 Sell 06-Jun-2022 15:23
7(2) SRJR LIFESCIENCES LLP 14756 1750345 Sell 06-Jun-2022 14:35
7(2) MAHAVEER CHAND BAFNA HUF 15823 0 Pledge Invoke 02-Sep-2021 17:00
7(2) MAHAVEER CHAND BAFNA 148507 0 Pledge Invoke 02-Sep-2021 17:00
7(2) PARAS BAFNA 41167 0 Pledge Invoke 02-Sep-2021 17:00
7(2) SASIKALA BAFNA 62757 0 Pledge Invoke 02-Sep-2021 17:00
7(2) AMRIBAI BAFNA 50000 0 Pledge Invoke 02-Sep-2021 17:00
7(2) Chetna Bafna 213280 0 Sell 31-May-2021 17:52
7(2) SRJR Lifesciences LLP 21290701 553558226 Buy 28-Dec-2020 18:20

Annual Reports of Bafna Pharmaceuticals Limited

Company From Year To Year Att.
Bafna Pharmaceuticals Limited 2023 2024
Bafna Pharmaceuticals Limited 2022 2023
Bafna Pharmaceuticals Limited 2021 2022
Bafna Pharmaceuticals Limited 2020 2021
Bafna Pharmaceuticals Limited 2019 2020

Investor Complaints of Bafna Pharmaceuticals Limited

Event Calendar of Bafna Pharmaceuticals Limited

Company Purpose Details Date
Bafna Pharmaceuticals Limited Financial Results/Other business matters To consider and approve the financial results for the period ended March 31, 2020 and other business matters 25-Jun-2020
Bafna Pharmaceuticals Limited Financial Results/Other business matters To consider and approve the financial results for the period ended Jun 30, 2020 and other business matters 10-Sep-2020
Bafna Pharmaceuticals Limited Financial Results/Other business matters To consider and approve the financial results for the period ended September 30, 2020 and other business matters 12-Nov-2020
Bafna Pharmaceuticals Limited Financial Results/Other business matters To consider and approve the financial results for the period ended December 31, 2020 and other business matters 12-Feb-2021
Bafna Pharmaceuticals Limited Financial Results/Other business matters To consider and approve the financial results for the period ended March 31, 2021 and other business matters 25-Jun-2021
Bafna Pharmaceuticals Limited Financial Results/Other business matters To consider and approve the financial results for the period ended Jun 30, 2021 and other business matters 05-Aug-2021
Bafna Pharmaceuticals Limited Other business matters To consider other business matters 16-Sep-2021
Bafna Pharmaceuticals Limited Financial Results/Other business matters To consider and approve the financial results for the period ended September 30, 2021 and other business matters 12-Nov-2021
Bafna Pharmaceuticals Limited Fund Raising/Other business matters To consider Fund Raising and other business matters 12-Nov-2021
Bafna Pharmaceuticals Limited Financial Results/Other business matters To consider and approve the financial results for the period ended December 31, 2021 and other business matters 10-Feb-2022
Bafna Pharmaceuticals Limited Other business matters Bafna Pharmaceuticals Limited has informed the Exchange about Board Meeting to be held on 21-Mar-2022 to consider resignation and appointment of Company Secretary and Compliance officer of the Company and any other business matters with the permission of Chair. 21-Mar-2022
Bafna Pharmaceuticals Limited Financial results Bafna Pharmaceuticals Limited has informed the Exchange about Board Meeting to be held on 11-Aug-2022 to consider financial statements for the period ended June 2022 11-Aug-2022
Bafna Pharmaceuticals Limited Financial results Bafna Pharmaceuticals Limited has informed the Exchange about Board Meeting to be held on 11-Nov-2022 to consider the un audited results for the Half year and Quarter ended period ended 30th September 2022 11-Nov-2022
Bafna Pharmaceuticals Limited Financial Results To consider and approve the Unaudited financial results for the Nine Months period and Quarter ended December 31, 2022 08-Feb-2023
Bafna Pharmaceuticals Limited Other business matters To Consider The Appointment Of Company Secretary Cum Compliance Officer And Any Other Business With The Permission Of The Chair 07-Apr-2023
Bafna Pharmaceuticals Limited Financial Results BAFNAPH : 27-May-2023 : The Company has informed the Exchange that a Board meeting to be held on May 24, 2023 has been re-scheduled. Further, the Company has informed the Exchange that the meeting of the Board of Directors of the Company will be held on May 27, 2023, To consider and approve the financial results for the period ended March 31, 2023 24-May-2023
Bafna Pharmaceuticals Limited Financial Results To consider and approve the financial results for the period ended March 31, 2023 24-May-2023
Bafna Pharmaceuticals Limited Other business matters To consider and approve the appointment of 1. Mr. Vinayak Dinesh Dendukuri (DIN: 07601309) as Additional Director designated as Whole-time Director Operation.2. Mr. Upendar Mekala Reddy (DIN: 08898174) as Additional Director designated as Non-Executive Non-independent Director;3. Mr. Krishna Yeachuri (DIN: 00066898) as Additional Director designated as Non-Executive Independent Director, and any other business with the permission of the Chair. 26-Jun-2023
Bafna Pharmaceuticals Limited Financial Results To consider and approve the financial results for the period ended Jun 30, 2023 11-Aug-2023
Bafna Pharmaceuticals Limited Financial Results To consider and approve the financial results for the period ended September 30, 2023 09-Nov-2023
Bafna Pharmaceuticals Limited Financial Results To consider and approve the un-audited financial results for the period ended December 31, 2023 12-Feb-2024
Bafna Pharmaceuticals Limited Financial Results To consider and approve the Audited Financial Results of the Company for the quarter and year ended March 31, 2024 29-May-2024
Bafna Pharmaceuticals Limited Financial Results To consider and approve the Unaudited financial results for the period ended Jun 30, 2024 13-Aug-2024
Bafna Pharmaceuticals Limited Financial Results To consider and approve the Unaudited Financial Results for the period ended September 30, 2024 11-Nov-2024
Bafna Pharmaceuticals Limited Financial Results To consider and approve the unaudited financial results for the period ended December 31, 2024 06-Feb-2025

Share Transfers of Bafna Pharmaceuticals Limited

Company Period Reg.7 Reg.40 Reg7 Bcast Date Reg40 Bcast Date
Bafna Pharmaceuticals Limited 31-MAR-2024 24-Apr-2024 18:00:04 22-Apr-2024 18:10:08
Bafna Pharmaceuticals Limited 31-MAR-2023 15-Apr-2023 16:30:06 12-Apr-2023 19:00:20
Bafna Pharmaceuticals Limited 31-MAR-2022 07-Apr-2022 15:50:27 11-Apr-2022 11:00:11
Bafna Pharmaceuticals Limited 31-MAR-2021 09-Apr-2021 12:10:09 27-Apr-2021 18:30:09
Bafna Pharmaceuticals Limited 30-SEP-2020 13-Oct-2020 15:50:16 23-Oct-2020 18:00:15
Bafna Pharmaceuticals Limited 31-MAR-2020 07-May-2020 11:10:02 28-May-2020 11:20:02

Voting Results of Bafna Pharmaceuticals Limited

Date of Mtg. Mtg. Type Resolution R. required Total SHs % favour % against
25-SEP-2024 AGM Adoption of Audited Financial Statements of the Company for the financialnyear ended March 31, 2024, together with the Reports of the Board ofnDirectors and Auditor¬タルs thereon. Ordinary 7421 100 0
25-SEP-2024 AGM Ratification of Remuneration of Cost Auditors M/s. N Sivashankaran andnCo., Cost Accountants (ICMAI FRN. 100662) for the F.Y 2024-25. Ordinary 7421 99.99 0.01
25-SEP-2024 AGM Sale / Disposal of Manufacturing Unit of the Company located at Madhavaram, Chennai, Tamil Nadu Special 7421 100 0
25-SEP-2024 AGM Re-appointment of Ms. Shanmugam Hemalatha (DIN: 02714329), as Whole-nTime Director of the Company, for a period of 5 years Ordinary 7421 99.99 0.01
25-SEP-2024 AGM Re-appointment of Mr. Upendar Mekala Reddy (DIN: 08898174), as Director ofnthe Company, who retires by rotation and being eligible, offers himself fornre-appointment. Ordinary 7421 99.99 0.01
22-SEP-2023 AGM Adoption of Financial Statements:To receive, consider and adopt the Audited financial statements of the Company for the financial year ended March 31, 2023, the Reports of the board of Directors¬タル and Auditor¬タルs thereon. Ordinary 7069 100 0
22-SEP-2023 AGM Appointment of Mr Krishna Yeachuri (DIN: 00066898) as a Non executive Independent Director of the Company Special 7069 100 0
22-SEP-2023 AGM Appointment of MR Upendar Mekala Redday (DIN :08898174) as a Non-executive Director of the Company Ordinary 7069 100 0
22-SEP-2023 AGM Appointment of Shri Vinayak Dinesh Dendukuri (DIN: 07601309) as a Director and Whole-time Director Special 7069 100 0
22-SEP-2023 AGM To appoint M/s N Sivashankaran & Co., Cost Accountant as cost auditor of the Company and to fix their remuneration. Ordinary 7069 100 0
22-SEP-2023 AGM To appoint Mrs. Akila Chintalapati Raju (DIN: 07590312) as director liable to retire by rotation and being eligible offers herself for re-appointment. Ordinary 7069 100 0
28-JUL-2022 AGM Adoption of Financial Statements for the financial year ended March 31, 2022 Ordinary 7331 100 0
28-JUL-2022 AGM To ratify the remuneration payable to M/s Sivashankaran and Co, Cost Auditor for the year 2022 -2023 Ordinary 7331 100 0
28-JUL-2022 AGM To appoint M/s BRAHMAYYA & Co, Chartered Accountants as statutory auditors of the Company and to fix their remuneration Ordinary 7331 100 0
28-JUL-2022 AGM To appoint Mrs. Akila Chintalapati Raju (DIN: 07590312) as director liable to retire by rotation and being eligible offers himself for re appointment Ordinary 7331 100 0
14-AUG-2021 AGM Adoption of Financial Statements Ordinary 8398 100 0
14-AUG-2021 AGM Regularisation of appointment of Mr. Atul Sachdeva (DIN:07645130) as a Director (Non Executive and Non- Independent) Ordinary 8398 100 0
14-AUG-2021 AGM Regularisation of appointment of Mrs. Ravichandran Chitra (DIN:07749125) as an Independent Non Executive Director Ordinary 8398 100 0
14-AUG-2021 AGM Regularisation of appointment of Mrs. Akila C Raju (DIN:07590312) as a Director (Non Executive and Non- Independent) Ordinary 8398 100 0
14-AUG-2021 AGM Regularisation of appointment of Ms. S.Hemalatha (DIN:02714329) as Whole-Time Director Ordinary 8398 100 0

FAQs on Bafna Pharmaceuticals Limited

Disclaimer: The information provided here is for informational purposes only and should not be considered financial advice. Please do your own research and consult with a financial professional before making any investment decisions.